Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrazoloacridine in Advanced NSCLC
NCT00002656Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Oct 1995
- Primary completion
- Dec 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrazoloacridine in non-small cell lung cancer (NSCLC), sponsored by Barbara Ann Karmanos Cancer Institute. Primary endpoint: Qualitative and quantitative toxicities of pyrazoloacridine. Started Oct 1995; status: completed.
02
Drugs
pyrazoloacridine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00002656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002656.